中国P站

Neurocysticercosis; Taenia solium; Epilepsy; Neuroimaging; Antiparasitic drugs; Host-parasite interaction; Public health; Neurological sequelae; Serological diagnosis; Hydrocephalus

Introduction

Neurocysticercosis stands as a profoundly significant global health issue, recognized as a leading cause of acquired epilepsy, especially within regions where it is endemic [1].

This formidable condition is directly attributed to the larval stage of Taenia solium, the pork tapeworm, which invades and establishes itself within the central nervous system [1].

The diagnostic pathway for neurocysticercosis is inherently multimodal, necessitating the integration of neuroimaging findings, specific serological tests, and crucial epidemiological data [1].

Therapeutic strategies for neurocysticercosis are multifaceted, commonly involving antiparasitic agents, anti-inflammatory medications, and anticonvulsants, with surgical intervention reserved for cases with symptomatic lesions [1].

The underlying pathogenesis of neurocysticercosis is characterized by an inflammatory response elicited by the presence of the Taenia solium cysticercus within the brain parenchyma, ventricles, or subarachnoid space [2].

This inflammatory cascade can precipitate a spectrum of neurological manifestations, ranging from seizures and persistent headaches to focal neurological deficits [2].

Advanced imaging techniques, prominently Magnetic Resonance Imaging (MRI), are instrumental in the definitive diagnosis of neurocysticercosis, enabling the clear visualization of cysts and associated inflammatory changes [3].

Effectively controlling the transmission of Taenia solium is paramount to diminishing the overall burden of neurocysticercosis, emphasizing the need for public health initiatives targeting sanitation and food safety [4].

Parenchymal neurocysticercosis management typically involves anthelmintic drugs such as albendazole or praziquantel, with treatment effectiveness potentially influenced by cyst stage and host inflammatory status [5].

When neurocysticercosis affects the ventricular and cisternal spaces, it can lead to obstructive hydrocephalus, often demanding urgent medical and sometimes surgical intervention to alleviate intracranial pressure [6].

Description

Neurocysticercosis, a parasitic infection of the central nervous system by the larval stage of the pork tapeworm Taenia solium, represents a major global public health concern and a primary cause of acquired epilepsy worldwide, particularly in endemic areas [1].

The diagnosis of neurocysticercosis is complex and relies on a thorough evaluation that integrates neuroimaging, serological evidence of infection, and relevant epidemiological information [1].

Treatment protocols for neurocysticercosis are tailored to the individual patient and disease manifestation, typically encompassing antiparasitic drugs, anti-inflammatory agents to manage the host response, and anticonvulsants to control seizures, with surgery being an option for specific symptomatic cases [1].

The pathogenesis involves a vigorous inflammatory reaction within the brain parenchyma, ventricles, or subarachnoid space, triggered by the presence of the parasite's cysticercus [2].

This immune response can lead to a variety of neurological symptoms, including seizures, which are a hallmark of the disease, as well as headaches and localized neurological deficits depending on lesion location [2].

Neuroimaging, especially MRI, plays a critical role in identifying the cysts and associated inflammatory changes, although differentiating neurocysticercosis from other intracranial pathologies can be challenging [3].

The control of Taenia solium transmission is a cornerstone of public health efforts to reduce neurocysticercosis incidence, requiring interventions related to sanitation, safe food handling practices, and deworming programs for both humans and pigs [4].

Medical management of parenchymal neurocysticercosis commonly utilizes albendazole or praziquantel, with adjunctive corticosteroids frequently administered to mitigate inflammation and cerebral edema [5].

Cases involving ventricular and cisternal neurocysticercosis may necessitate surgical management, such as shunting procedures or endoscopic interventions, to address obstructive hydrocephalus and relieve increased intracranial pressure [6].

The long-term consequences of neurocysticercosis, even after effective treatment of the cysts, can include persistent epilepsy and cognitive deficits, highlighting the importance of ongoing neurological follow-up [7].

Conclusion

Neurocysticercosis, caused by the larval stage of the pork tapeworm Taenia solium, is a significant cause of acquired epilepsy globally, particularly in endemic regions. Diagnosis involves neuroimaging, serology, and epidemiological data. Management includes antiparasitic drugs, anti-inflammatories, anticonvulsants, and sometimes surgery. The pathogenesis involves an inflammatory response within the CNS, leading to neurological symptoms like seizures and headaches. MRI is crucial for diagnosis, though differential diagnosis can be challenging. Control of Taenia solium transmission through public health initiatives is vital. Treatment for parenchymal forms typically involves albendazole or praziquantel with corticosteroids, while ventricular forms may require surgical intervention. Long-term neurological sequelae can include chronic epilepsy and cognitive impairments. Serological diagnosis is a valuable tool, and the economic burden of the disease is substantial. Understanding the host immune response is key for developing new therapies. Research continues into immunotherapeutic strategies and effective control measures.

References

1. Garcia H, Preux P, Verastgui R. (2022) .J Neuroinfect Dis 13:13(1):15-25.

   , ,

2. Santana-Rodriguez A, Flisser A, Diaz-Campos N. (2021) .Front Neurol 12:12:701573.

   , ,

3. Odabas A, Ozbilge H, Gonenli S. (2020) .Radiographics 40:40(6):1675-1688.

   , ,

4. Dominguez-Reyes A, Proano E, Cabrera R. (2023) .PLoS Negl Trop Dis 17:17(1):e0010937.

   , ,

5. Agostini G, Posadas S, Costa-Luz M. (2020) .J Neuroparasitol 11:11(2):105-113.

   , ,

6. Montes G, Reyes J, Hernandez-Perez M. (2021) .World Neurosurg 151:151:e317-e325.

   , ,

7. Vallejo J, Mejia L, Jimenez A. (2022) .J Neurol Sci 432:432:120112.

   , ,

8. Gonzalez-Alegre P, Romero-Lopéz J, Sosa-Gomez V. (2020) .Clin Microbiol Rev 33:33(3):e00036-19.

   , ,

9. MacDonald N, Kruse A, Chai S. (2023) .Health Policy Plan 38:38(1):101-111.

   , ,

10. Fernandez-Diego J, Perez-Gutierrez M, Torres-Gomez J. (2021) .Parasite Immunol 43:43(5):e12810.

    , ,